Drug General Information (ID: DDIJMDUV8I)
  Drug Name Liothyronine Drug Info Doxepin (topical) Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Hormone Replacement Agents Antidepressants
  Structure

 Mechanism of Liothyronine-Doxepin (topical) Interaction (Severity Level: Moderate)
     Potentiated the pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
      Drug Name Liothyronine Doxepin (topical)
      Mechanism 1 Potentiate the effects of tricyclic antidepressant by increasing the sensitivity of receptors to catecholamines Tricyclic antidepressants
      Key Mechanism Factor 1
Factor Name Pharmacodynamics
Factor Description Enhanced pharmacological effects leading to increased adverse reactions.
      Mechanism Description
  • Potentiate the pharmacologic effects by the combination of Liothyronine and Doxepin (topical) 
      Mechanism 2 Potentiate the effects of tricyclic antidepressant by increasing the sensitivity of receptors to catecholamines Tricyclic antidepressant
      Key Mechanism Factor 2
Factor Name Pharmacodynamics
Factor Description Enhanced pharmacological effects leading to increased adverse reactions.
      Mechanism Description
  • Potentiate the pharmacologic effects by the combination of Liothyronine and Doxepin (topical) 

Recommended Action
      Management Patients receiving concomitant thyroid hormone replacement therapy and tricyclic antidepressant therapy should be closely monitored for cardiac arrhythmias and CNS stimulation. Advise patients to contact their doctor if they experience toxicity symptoms such as: anxiety, agitation, insomnia, shortness of breath, irregular or fast heartbeat, and lightheadedness or dizziness.

References
1 Product Information. Synthroid (levothyroxine). Abbott Pharmaceutical, Abbott Park, IL.
2 Product Information. Triostat (liothyronine). JHP Pharmaceuticals, Saddle River, NJ.
3 Goodwin FK, Prange AJ Jr, Post RM, Muscettola G, Lipton MA "Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders." Am J Psychiatry 139 (1982): 34-8